Samarth Kulkarni, CEO, CRISPR Therapeutics

Kulkarni discusses the current state of biotechnology, the opportunities for CRISPR gene-editing therapies - and their implications for the larger pharmaceutical industry - as well as his experience leading a young company at the cutting edge of technology.
Record Date: 2/14/23